Drug Profile
Research programme: stem cell therapeutics - BioRestorative Therapies
Alternative Names: Metabolic Program - BioRestorative Therapies; ThermoStemLatest Information Update: 14 Dec 2023
Price :
$50
*
At a glance
- Originator BioRestorative Therapies
- Class Antihyperglycaemics; Antihypertensives; Cardiovascular therapies; Obesity therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Diabetes mellitus; Metabolic disorders; Obesity
- No development reported Cardiovascular disorders; Hypertension
Most Recent Events
- 13 Dec 2023 United States Patent and Trademark Office (USPTO) issues a notice of allowance for BRTX 100 for methods of using differentiated human brown fat adipocytes
- 08 May 2023 BioRestorative Therapies receives notice of allowance for a patent related to ThermoStem® program in Japan
- 24 Feb 2023 BioRestorative Therapies receives patent allowance for ThermoStem programme in USA